Skip to main content

Table 1 Main baseline characteristics of patients with circulatory shock

From: Skin microcirculatory reactivity assessed using a thermal challenge is decreased in patients with circulatory shock and associated with outcome

Variable

Initial cohort

Confirmatory cohort

Total (n = 29)

Survivors (n = 18)

Non-survivors (n = 11)

P

Total (n = 35)

Survivors (n = 17)

Non-survivors (n = 18)

P

Age (years)

67 ± 11

64 ± 12

71 ± 8

0.11

64 ± 16

61 ± 16

67 ± 16

0.30

Body mass index (kg/m2)

26 ± 6

25 ± 5

27 ± 8

0.66

28 ± 5

27 ± 5

28 ± 5

0.29

Septic shock [n (%)]

16 (55)

9 (50)

7 (64)

0.82

28 (80)

13 (77)

15 (83)

0.61

Cardiogenic shock [n (%)]

13 (45)

9 (50)

4 (36)

0.82

7 (20)

4 (23)

3 (17)

0.61

Chronic kidney disease [n (%)]

8 (28)

7 (39)

1 (9)

0.11

8 (23)

4 (24)

4 (22)

1.00

Chronic arterial hypertension [n (%)]

20 (69)

11 (61)

9 (82)

0.41

11 (31)

5 (29)

6 (33)

0.80

Diabetes mellitus [n (%)]

12 (41)

7 (39)

5 (46)

0.73

11 (31)

5 (29)

6 (33)

0.80

Coronary artery disease [n (%)]

9 (31)

5 (28)

4 (36)

0.69

8 (23)

3 (18)

5 (28)

0.69

Mean arterial pressure (mmHg)

75 ± 13

73 ± 9

77 ± 17

0.52

73 ± 9

72 ± 7

75 ± 10

0.28

Heart rate (bpm)

97 ± 25

99 ± 25

95 ± 27

0.67

99 ± 22

101 ± 22

98 ± 22

0.71

Central venous pressure (mmHg)

11 (8–12)

11 (7–12)

11 (9–13)

0.28

9 (7–12)

8 (6–11)

10 (8–12)

0.23

Cardiac output (L/min)

4.0 (3.4–5.7)

n = 18

3.8 (3.2–4.7)

n = 11

4.1 (3.5–6.8)

n = 7

0.44

4.8 (3.5–6.3)

n = 32

4.8 (3.4–6.7)

n = 16

4.6 (3.6–5.6)

n = 16

0.68

Central temperature (°C)

36.8 (36.0–37.5)

37.1 (36.2–37.8)

36.5 (35.9–37.3)

0.19

36.9 (36.6–37.5)

36.8 (36.6–37.2)

37.0 (36.6–37.6)

0.71

Basal forearm temperature (°C)

32.0 (31.1–32.7)

32.1 (31.1–32.7)

31.4 (30.7–32.7)

0.58

30.6 (29.1–31.6)

30.5 (28.9–31.6)

30.7 (30.0–31.8)

0.55

Central to basal forearm temperature (°C)

5.1 (4.2–6.1)

5.0 (4.5–6.4)

5.0 (4.2–5.6)

0.44

6.5 (5.6–7.6)

7.4 (5.2–7.9)

6.4 (5.8–7.1)

0.54

pH

7.35 ± 0.07

7.36 ± 0.06

7.33 ± 0.09

0.29

7.35 ± 0.12

7.33 ± 0.13

7.36 ± 0.11

0.42

PCO2 (mmHg)

38 ± 8

39 ± 9

35 ± 8

0.22

37 ± 11

40 ± 14

35 ± 8

0.22

Lactate (mmol/L)

2.4 (1.6–4.8)

1.9 (1.5–2.9)

3.2 (1.6–6.3)

0.35

1.7 (1.2–2.6)

1.6 (1.1–2.7)

1.8 (1.3–2.4)

0.78

Mechanical ventilation [n (%)]

25 (86)

15 (83)

10 (91)

1.00

25 (71)

10 (59)

15 (84)

0.11

PaO2/FiO2 ratio

192 (132–293)

196 (128–310)

192 (145–250)

0.93

166 (124–244)

189 (124–247)

146 (120–211)

0.24

Creatinine (mg/dL)

1.4 (1.0–1.7)

1.4 (0.9–1.6)

1.6 (1.0–2.2)

0.44

1.3 (0.8–2.0)

1.3 (0.8–1.9)

1.2 (0.8–2.1)

0.82

Total bilirubin (mg/dL)

0.9 (0.5–2.1)

0.9 (0.5–1.8)

1.6 (0.6–2.8)

0.30

0.8 (0.5–2.7)

0.8 (0.5–2.7)

0.9 (0.5–2.6)

0.58

Platelets (× 103/µL)

163 (92–243)

160 (92–243)

163 (65–307)

0.93

52 (13–79)

58 (25–108)

22 (7–67)

0.06

Leukocytes (cells × 103/µL)

12.4 (8.5–17.7)

11.7 (8.2–17.7)

12.4 (8.5–17.7)

0.95

12.0 (8.5–19.9)

12.5 (10.4–21.9)

10.8 (4.7–17.0)

0.16

Number of patients receiving sedatives [n (%)]

17 (59)

10 (56)

7 (64)

0.67

8 (23)

4 (24)

4 (22)

1.00

Number of patients receiving opiates [n (%)]

22 (76)

14 (78)

8 (73)

1.00

7 (20)

4 (24)

3 (17)

0.69

APACHE II score

26 ± 8

23 ± 7

30 ± 8

0.03

26 ± 8

22 ± 8

29 ± 6

< 0.01

SOFA score

10 ± 3

10 ± 3

12 ± 3

0.04

10 ± 5

9 ± 5

11 ± 4

0.13

Number of patients receiving dobutamine [n (%)]

13 (45)

7 (39)

6 (54)

0.41

6 (17)

2 (24)

2 (11)

0.40

Dobutamine dose at moment of thermal challenge (mcg/Kg/min)

0 (0–10)

0 (0–5)

10 (0–15)

0.24

0 (0–0)

0 (0–0)

0 (0–0)

0.42

Norepinephrine dose at moment of thermal challenge (mcg/Kg/min)

0.32 (0.11–0.50)

0.28 (0.11–0.41)

0.43 (0.11–0.84)

0.43

0.12 (0.08–0.55)

0.12 (0.07–0.41)

0.20 (0.08–0.62)

0.36

ICU length of stay (days)

8.0 (3.5–16.0)

8.6 (4.4–16.0)

6.5 (2.1–19.6)

0.44

5.3 (3.2–9.0)

4.7 (4.0–9.0)

6.0 (3.2–8.0)

0.70